Roy Baynes, Merck Research Laboratories CMO (file photo)
Looking to rebound from rejection in TNBC, Merck's Keytruda passes a new kidney cancer test
Keytruda has long been a dominant force in biopharma, racking up billions in sales for Merck and continuing to expand into more and more types …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
